




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 38/27, 38/25</b>		A3	(11) International Publication Number: <b>WO 00/13650</b>
			(43) International Publication Date: 16 March 2000 (16.03.00)
(21) International Application Number:	PCT/NZ99/00147	(81) Designated States:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	3 September 1999 (03.09.99)		
(30) Priority Data:	331719 3 September 1998 (03.09.98) NZ		
(71) Applicant (for all designated States except US):	NEURONZ LIMITED [NZ/NZ]; UniServices House, 58 Symonds Street, Auckland (NZ).		
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only):	SCHEEPENS, Arjan [NL/NZ]; 95 Elmore Road, RD3, Albany, Auckland (NZ). WILLIAMS, Chris, Edward [NZ/NZ]; 2/73B Carlton Gore Road, Grafton, Auckland (NZ). GLUCKMAN, Peter, David [NZ/NZ]; 78 Lucerne Road, Remuera, Auckland (NZ). CLARK, Ross, Graham [NZ/NZ]; 25 Glen Road, Devonport, Auckland (NZ).	With international search report.	
(74) Agents:	BENNETT, Michael, Roy et al.; West-Walker Bennett, Mobil on the Park, 157 Lambton Quay, Wellington (NZ).	(88) Date of publication of the international search report:	2 June 2000 (02.06.00)

## (54) Title: NEUROPROTECTION

## Effect of ICV rat GH treatment on neuronal score following moderate HI



## (57) Abstract

The invention relates to neuroprotection and to medicaments for use therein. Neuroprotection is induced by activation of neural growth hormone receptors, primarily using medicaments comprising growth hormone, growth hormone analogs or ligands which are functionally equivalent. Such medicaments may also include one or more secondary neuroprotective agents.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ 99/00147

## A. CLASSIFICATION OF SUBJECT MATTER

Int Cl<sup>7</sup>: A61K 38/27; 38/25

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>6</sup>: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPAT: BRAIN, GROWTH HORMONE, PROLACTIN, LACTOGEN, IGF-1, GRP, activin, NGF, TGF- $\beta$ , bfgf

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/16242 (Regeneron Pharmaceuticals Inc) 23 April 1998	1-29
X	WO 94/23754 (THE COMMONWEALTH OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES) 27 October 1994	1-17,19,27,28,29
X	JP 2-67223 (DAI ICHI SEIYAKU CO LTD) 7 March 1990	1-18

Further documents are listed in the continuation of Box C

See patent family annex

\* Special categories of cited documents:

"A" Document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier application or patent but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "X" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
 "&" document member of the same patent family

Date of the actual completion of the international search  
 14 March 2000

Date of mailing of the international search report  
 22 MAR 2000

Name and mailing address of the ISA/AU  
 AUSTRALIAN PATENT OFFICE  
 PO BOX 200  
 WODEN ACT 2606 AUSTRALIA  
 E-mail address: pct@ipaaustralia.gov.au  
 Facsimile No.: (02) 6285 3929

Authorized officer  
 A. WILCOX  
 Telephone No.: (02) 6283 2243

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/NZ 99/00147

C (Continuation). <b>DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 357240 (ETHICON INC) 7 March 1990	1-18
X	WO 91/14838 (CEPHALON INC) 13 December 1990	1-29
X	WO 93/08828 (SYNTEX-SYNERGEN NEURO SCIENCE JOINT VENTURE and THE GENERAL HOSPITAL CORPORATION) 13 May 1993	1-8,24-29
X	WO 96/40871 (CYTOTHERAPEUTICS, INC) 19 December 1996	1-18
X	WO 97/17090 (BAYLOR COLLEGE OF MEDICINE) 15 May 1997	1-29
X	AU 32571/97 (BOEHRINGER MANNHEIM GmbH) 18 December 1997	1-29
X	US 5750376 (NEUROSPHERES HOLDINGS LTD) 12 May 1998	1-29
X	WO 91/07947 (RAMSEY FOUNDATION) 13 June 1991	1-29

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/NZ 99/00147

### Box 1 Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

### Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The method of neuroprotection in the brain by administration of growth hormone is not novel. The claims to methods using analogues of growth hormone are considered to be directed to separate inventions. The claims lack special or novel technical features.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
**PCT/NZ 99/00147**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member				
WO	98/16242	EP	938333				
WO	94/23754	AU	65312/94	CA	2159738	EP	696205
		US	5690927	US	5753491	US	5869463
		AU	60363/96	BR	9609154	CA	2221258
		CN	1192781	EP	832203	NZ	310048
		WO	96/39496				
JP	2-67223	JP	61143684				
EP	357240	AU	39244/89	CA	1332351	JP	2083334
		US	5057494	ZA	8905910		
WO	91/14838	AU	73633/91	CA	2057915	GB	2248248
		IT	1249409	NZ	237522	US	5299836
		FR	2659998	ZA	9101975		
WO	93/08828	AU	31297/93	US	5733871		
WO	96/40871	AU	61053/96	US	5837234		
WO	97/17090	AU	77195/96				
AU	32571/97	WO	97/47735	WO	97/47737	CN	1222191
US	5750376	AU	22425/92	CA	2113118	EP	594669
		FI	935929	NO	940056	WO	93/01275
		WO	94/16718	US	5981165	US	5750376
		US	5851832	US	5980885	AU	51474/93
		CA	2147162	EP	664832	FI	951677
		NO	951378	WO	94/09119	AU	53676/94
		AU	49241/97	EP	669973	FI	952022
		NO	951617	WO	94/10292	AU	60983/94
		CA	2155024	EP	681477	FI	953569
		NO	952985	AU	80561/94	CA	2175992
		CN	1141058	EP	728194	FI	961855
		NO	961859	WO	95/13364	AU	35152/95
		CA	2200709	EP	783693	FI	971168
		NO	971245	WO	96/09543	AU	38367/95
CONTINUED							

Patent Document Cited in Search Report			Patent Family Member		
	CN 1170435		EP 792350		FI 971956
	NO 972171		WO 96/15226		AU 38366/95
	CN 1170434		EP 792349		FI 971955
	NO 972170		WO 96/15224		
WO 91/07947	AU 69090/91		CA 2070823		EP 504263
	US 5624898				
END OF ANNEX					